Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436

Watchlist Manager
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Logo
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Watchlist
Price: 206.1 CNY 0.52% Market Closed
Market Cap: 124.3B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Zhangzhou Pientzehuang Pharmaceutical Co Ltd stock under the Base Case scenario is 156.73 CNY. Compared to the current market price of 206.1 CNY, Zhangzhou Pientzehuang Pharmaceutical Co Ltd is Overvalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
156.73 CNY
Overvaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

11.4
P/S
P/S
Price to Sales
11.4
vs History
93
vs Industry
12
Median 3Y
17.2
Median 5Y
18.9
Industry
2.4
Forward
10.9
More Details
40.4
P/E
P/E
Price to Earnings
40.4
vs History
93
vs Industry
11
Median 3Y
58.8
Median 5Y
67.2
Industry
20.6
Forward
39
More Details
110.4
P/OCF
P/OCF
Price to OCF
110.4
vs History
31
vs Industry
4
Median 3Y
61.1
Median 5Y
66.2
Industry
15.5
More Details
103.4
P/FCFE
P/FCFE
Price to FCFE
103.4
vs History
34
vs Industry
5
Median 3Y
62.2
Median 5Y
64.2
Industry
23
More Details
8.9
P/B
P/B
Price to Book Value
8.9
vs History
92
vs Industry
7
Median 3Y
12.8
Median 5Y
14.8
Industry
1.9
More Details
11.2
EV/S
EV/S
Enterprise Value to Sales
11.2
vs History
88
vs Industry
12
Median 3Y
17
Median 5Y
18.7
Industry
2.5
Forward
10.7
More Details
25.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
25.5
vs History
87
vs Industry
8
Median 3Y
37.1
Median 5Y
40.6
Industry
4.9
More Details
34.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
34.6
vs History
88
vs Industry
10
Median 3Y
50.5
Median 5Y
57.5
Industry
12.6
Forward
31.8
More Details
34.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
34.6
vs History
88
vs Industry
13
Median 3Y
50.5
Median 5Y
57.5
Industry
15.7
Forward
32.7
More Details
108.5
EV/OCF
EV/OCF
Enterprise Value to OCF
108.5
vs History
31
vs Industry
4
Median 3Y
57.7
Median 5Y
64.7
Industry
14
More Details
121.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
121.3
vs History
33
vs Industry
4
Median 3Y
61.1
Median 5Y
69.1
Industry
17.7
More Details
8.5
EV/IC
EV/IC
Enterprise Value to IC
8.5
vs History
93
vs Industry
10
Median 3Y
15.1
Median 5Y
21.9
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
124.3B CNY 11.4 40.4 34.6 34.6
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
CN
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Average P/E: 27.8
40.4
15%
2.7
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Average EV/EBIT: 1 700.7
34.6
14%
2.5
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 249,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.